Recursion Pharmaceuticals, INC Form 4 insider transactions

Christopher Gibson, CEO of Recursion Pharmaceuticals, reported the sale of 40,000 shares of Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Director Zavain Dar acquired 1,907 shares of Recursion Pharmaceuticals Class A Common Stock on January 2, 2025, as part of the company's Outside Director Compensation Policy.

Director Dean Y. Li acquired 1,647 shares of Class A Common Stock in Recursion Pharmaceuticals through the company's Outside Director Compensation Policy.

Director Blake Borgeson acquired 1,734 shares of Recursion Pharmaceuticals Class A Common Stock as part of the company's Outside Director Compensation Policy.

Chief Financial Officer of Recursion Pharmaceuticals, Ben R. Taylor, reports the acquisition of restricted stock units and stock options, along with adjustments to his holdings of Class A Common Stock.

Recursion Pharmaceuticals' Chief Financial Officer, Ben R. Taylor, sold shares of Class A Common Stock to cover tax obligations related to the vesting of restricted stock units.

Recursion Pharmaceuticals CEO, Christopher Gibson, executed pre-planned transactions involving the conversion and sale of Class A and Class B common stock, as detailed in a recent SEC Form 4 filing.

Director Franziska Michor reported acquiring shares and options in Recursion Pharmaceuticals following the acquisition of Exscientia.

David J. Mauro, Chief Medical Officer of Recursion Pharmaceuticals, sold 4,187 shares of Class A Common Stock to cover tax obligations related to restricted stock units.

Recursion Pharmaceuticals' Chief Financial Officer, Michael Secora, sold 11,937 shares of Class A Common Stock to cover tax obligations related to the vesting of restricted stock units.

Tina Marriott, President and COO of Recursion Pharmaceuticals, sold 14,286 shares of Class A Common Stock to cover tax obligations related to restricted stock units.

Christopher Gibson, CEO of Recursion Pharmaceuticals, reports the withholding of 26,023 shares for tax obligations and provides an update on his holdings of Class A and Class B common stock and stock options.

Recursion Pharmaceuticals CEO, Christopher Gibson, executed multiple transactions involving the conversion and sale of Class A Common Stock under a pre-arranged 10b5-1 trading plan.

A Recursion Pharmaceuticals director, Blake Borgeson, sold 11,447 shares of Class A Common Stock at an average price of $7.6402 per share under a pre-arranged 10b5-1 trading plan.

Recursion Pharmaceuticals' Chief Financial Officer, Michael Secora, executed multiple stock option exercises and sales under a pre-arranged 10b5-1 trading plan.

Director Blake Borgeson of Recursion Pharmaceuticals sold 11,447 shares of Class A Common Stock at an average price of $6.7202, according to a Form 4 filing.

Tina Marriott, President and COO of Recursion Pharmaceuticals, executed a stock option and sold 6,000 shares of Class A Common Stock at an average price of $6.3091, according to a recent SEC filing.

Director Blake Borgeson of Recursion Pharmaceuticals sold 11,447 shares of Class A Common Stock at an average price of $6.6678 per share on October 15, 2024, under a pre-arranged 10b5-1 trading plan.

Michael Secora, CFO of Recursion Pharmaceuticals, exercised stock options and sold shares of Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Blake Borgeson, a director at Recursion Pharmaceuticals, acquired 2,026 shares of Class A Common Stock on October 1, 2024, under the company's Outside Director Compensation Policy.

Director Zavain Dar acquired 2,229 shares of Recursion Pharmaceuticals' Class A Common Stock on October 1, 2024, under the company's Outside Director Compensation Policy.

Christopher Gibson, CEO of Recursion Pharmaceuticals, executed sales of Class A Common Stock on October 2nd and 3rd, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Dean Y. Li acquired 1,925 shares of Recursion Pharmaceuticals' Class A Common Stock on October 1, 2024, under the company's Outside Director Compensation Policy.

Blake Borgeson, a director at Recursion Pharmaceuticals, sold 11,447 shares of Class A Common Stock at an average price of $6.2156 on October 1, 2024, under a pre-arranged 10b5-1 trading plan.

Tina Marriott, President and COO of Recursion Pharmaceuticals, exercised stock options and sold 6,000 shares of Class A Common Stock at an average price of $7.0008, pursuant to a pre-arranged 10b5-1 trading plan.

Director Blake Borgeson of Recursion Pharmaceuticals sold 11,447 shares of Class A Common Stock at a weighted average price of $6.8431 per share, executed under a pre-arranged 10b5-1 trading plan.

Chief Financial Officer of Recursion Pharmaceuticals, Michael Secora, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Christopher Gibson, CEO of Recursion Pharmaceuticals, executed sales of Class A Common Stock on September 4th and 5th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals (RXRX) under a pre-arranged Rule 10b5-1 trading plan.

Tina Marriott, President and COO of Recursion Pharmaceuticals, exercised stock options and sold 6,000 shares of Class A Common Stock on August 29, 2024, under a pre-arranged 10b5-1 trading plan.